METASTATIC GASTRIC CANCER

This study is testing whether adding a new two-drug immunotherapy (called QL1706) to standard chemotherapy works better for people with advanced stomach or gastroesophageal junction cancer who haven't had prior treatment. About 32 participants will receive the combination therapy…

This study is testing a new combination of two cancer drugs, disitamab vedotin and tucatinib, for people with advanced or spreading breast or stomach cancer. The main goals are to find a safe and effective dose and to see if the combination can shrink tumors. It is for people who…

This study is testing whether adding a new oral drug called SHR2554 to other cancer treatments is safe and effective for people with advanced stomach cancer that has spread or cannot be removed by surgery. It will involve about 351 adults with this condition. The main goals are t…

This is the first human study testing a new drug called IPH5301 for people with advanced cancers that have spread. The trial has two parts: first finding the safest dose of IPH5301 alone, then testing it combined with standard chemotherapy in breast cancer patients. It's for adul…

This is the first study in people to test a new oral drug called NKT3964. It aims to see if the drug is safe and can help control advanced cancers that have spread and stopped responding to standard treatments. The study will enroll adults with specific advanced solid tumors, inc…

This study is testing a new combination of five different treatments for people with advanced stomach or esophageal cancer that has worsened after one prior therapy. The goal is to see if this multi-drug approach can better control the cancer. The treatment includes two immunothe…

This study is testing if giving a standard cancer drug (paclitaxel) over a longer time to patients with low muscle mass results in drug levels similar to those seen in patients with normal muscle mass. The goal is to see if this personalized timing approach could make the treatme…